nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.06	0.134	CbGpPWpGaD
Epoprostenol—PTGIS—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.0451	0.101	CbGpPWpGaD
Epoprostenol—PTGIS—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0245	0.0547	CbGpPWpGaD
Epoprostenol—PTGIS—Nicotinamide salvaging—PTGS2—thyroid cancer	0.0184	0.0411	CbGpPWpGaD
Epoprostenol—PTGER1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0179	0.04	CbGpPWpGaD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0179	0.04	CbGpPWpGaD
Epoprostenol—PTGIS—Arachidonic acid metabolism—HPGD—thyroid cancer	0.0163	0.0363	CbGpPWpGaD
Epoprostenol—PTGIS—Synthesis of bile acids and bile salts via 27-hydroxycholesterol—RXRA—thyroid cancer	0.0154	0.0344	CbGpPWpGaD
Epoprostenol—PTGIS—Endogenous sterols—RXRA—thyroid cancer	0.011	0.0244	CbGpPWpGaD
Epoprostenol—PTGIS—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—RXRA—thyroid cancer	0.0106	0.0236	CbGpPWpGaD
Epoprostenol—PTGIS—Nicotinate metabolism—PTGS2—thyroid cancer	0.00981	0.0219	CbGpPWpGaD
Epoprostenol—PTGIS—Synthesis of bile acids and bile salts—RXRA—thyroid cancer	0.00963	0.0215	CbGpPWpGaD
Epoprostenol—PTGIS—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.00809	0.0181	CbGpPWpGaD
Epoprostenol—PTGIS—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.00765	0.0171	CbGpPWpGaD
Epoprostenol—PTGIR—G alpha (s) signalling events—CALCB—thyroid cancer	0.00715	0.016	CbGpPWpGaD
Epoprostenol—PTGIR—Endothelin Pathways—CALCA—thyroid cancer	0.00715	0.0159	CbGpPWpGaD
Epoprostenol—PTGIS—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.00526	0.0117	CbGpPWpGaD
Epoprostenol—PTGIS—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00508	0.0113	CbGpPWpGaD
Epoprostenol—PTGIS—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.0044	0.00981	CbGpPWpGaD
Epoprostenol—PTGIS—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00412	0.0092	CbGpPWpGaD
Epoprostenol—PTGIS—thyroid gland—thyroid cancer	0.00373	0.179	CbGeAlD
Epoprostenol—PTGIR—G alpha (s) signalling events—TSHR—thyroid cancer	0.00331	0.00739	CbGpPWpGaD
Epoprostenol—PTGIS—head—thyroid cancer	0.0033	0.159	CbGeAlD
Epoprostenol—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00322	0.00718	CbGpPWpGaD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00322	0.00718	CbGpPWpGaD
Epoprostenol—PTGER1—head—thyroid cancer	0.00307	0.148	CbGeAlD
Epoprostenol—P2RY12—head—thyroid cancer	0.00298	0.143	CbGeAlD
Epoprostenol—PTGIS—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00292	0.00652	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CALCB—thyroid cancer	0.00282	0.00629	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—RXRA—thyroid cancer	0.00274	0.00611	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00263	0.00587	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CALCB—thyroid cancer	0.0026	0.00579	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CALCB—thyroid cancer	0.0026	0.00579	CbGpPWpGaD
Epoprostenol—PTGIR—G alpha (s) signalling events—CALCA—thyroid cancer	0.00248	0.00553	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00233	0.00519	CbGpPWpGaD
Epoprostenol—PTGIS—lymph node—thyroid cancer	0.00231	0.111	CbGeAlD
Epoprostenol—PTGIS—Biological oxidations—RXRA—thyroid cancer	0.00219	0.00489	CbGpPWpGaD
Epoprostenol—PTGIR—thyroid gland—thyroid cancer	0.00214	0.103	CbGeAlD
Epoprostenol—PTGIS—Adipogenesis—HIF1A—thyroid cancer	0.00203	0.00454	CbGpPWpGaD
Epoprostenol—Pain—Vandetanib—thyroid cancer	0.00199	0.00374	CcSEcCtD
Epoprostenol—Pleural effusion—Doxorubicin—thyroid cancer	0.00196	0.00369	CcSEcCtD
Epoprostenol—Mental disorder—Sorafenib—thyroid cancer	0.00193	0.00364	CcSEcCtD
Epoprostenol—Skin ulcer—Doxorubicin—thyroid cancer	0.00193	0.00363	CcSEcCtD
Epoprostenol—Hyperaesthesia—Doxorubicin—thyroid cancer	0.00191	0.0036	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Vandetanib—thyroid cancer	0.0019	0.00358	CcSEcCtD
Epoprostenol—PTGIR—head—thyroid cancer	0.0019	0.0915	CbGeAlD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—thyroid cancer	0.00188	0.00419	CbGpPWpGaD
Epoprostenol—Vasodilation procedure—Epirubicin—thyroid cancer	0.00185	0.00348	CcSEcCtD
Epoprostenol—Vasodilation—Epirubicin—thyroid cancer	0.00185	0.00348	CcSEcCtD
Epoprostenol—Muscle spasms—Sorafenib—thyroid cancer	0.00185	0.00348	CcSEcCtD
Epoprostenol—Injection site pain—Doxorubicin—thyroid cancer	0.00184	0.00347	CcSEcCtD
Epoprostenol—Abdominal pain—Vandetanib—thyroid cancer	0.00184	0.00346	CcSEcCtD
Epoprostenol—Body temperature increased—Vandetanib—thyroid cancer	0.00184	0.00346	CcSEcCtD
Epoprostenol—Rectal haemorrhage—Epirubicin—thyroid cancer	0.0018	0.00339	CcSEcCtD
Epoprostenol—Cellulitis—Epirubicin—thyroid cancer	0.00179	0.00336	CcSEcCtD
Epoprostenol—Anaemia—Sorafenib—thyroid cancer	0.00178	0.00334	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—PPARG—thyroid cancer	0.00173	0.00386	CbGpPWpGaD
Epoprostenol—Syncope—Sorafenib—thyroid cancer	0.00172	0.00324	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00172	0.00383	CbGpPWpGaD
Epoprostenol—Vasodilation procedure—Doxorubicin—thyroid cancer	0.00171	0.00322	CcSEcCtD
Epoprostenol—Vasodilation—Doxorubicin—thyroid cancer	0.00171	0.00322	CcSEcCtD
Epoprostenol—Loss of consciousness—Sorafenib—thyroid cancer	0.00169	0.00318	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—SST—thyroid cancer	0.00168	0.00374	CbGpPWpGaD
Epoprostenol—Cough—Sorafenib—thyroid cancer	0.00168	0.00316	CcSEcCtD
Epoprostenol—Asthenia—Vandetanib—thyroid cancer	0.00167	0.00314	CcSEcCtD
Epoprostenol—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.00166	0.00313	CcSEcCtD
Epoprostenol—Cellulitis—Doxorubicin—thyroid cancer	0.00165	0.00311	CcSEcCtD
Epoprostenol—Pruritus—Vandetanib—thyroid cancer	0.00164	0.0031	CcSEcCtD
Epoprostenol—Neck pain—Epirubicin—thyroid cancer	0.00164	0.00309	CcSEcCtD
Epoprostenol—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00164	0.00309	CcSEcCtD
Epoprostenol—Myalgia—Sorafenib—thyroid cancer	0.00164	0.00308	CcSEcCtD
Epoprostenol—Arthralgia—Sorafenib—thyroid cancer	0.00164	0.00308	CcSEcCtD
Epoprostenol—PTGIS—Disease—TRIM24—thyroid cancer	0.00163	0.00364	CbGpPWpGaD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00162	0.00306	CcSEcCtD
Epoprostenol—Pulmonary embolism—Epirubicin—thyroid cancer	0.00162	0.00306	CcSEcCtD
Epoprostenol—Injection site reaction—Epirubicin—thyroid cancer	0.00161	0.00304	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—MINPP1—thyroid cancer	0.00161	0.00359	CbGpPWpGaD
Epoprostenol—Dry mouth—Sorafenib—thyroid cancer	0.0016	0.00301	CcSEcCtD
Epoprostenol—Hyperkalaemia—Epirubicin—thyroid cancer	0.0016	0.003	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CALCB—thyroid cancer	0.00159	0.00356	CbGpPWpGaD
Epoprostenol—Diarrhoea—Vandetanib—thyroid cancer	0.00159	0.00299	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00158	0.00352	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00158	0.00352	CbGpPWpGaD
Epoprostenol—Influenza like illness—Epirubicin—thyroid cancer	0.00158	0.00297	CcSEcCtD
Epoprostenol—Anaphylactic shock—Sorafenib—thyroid cancer	0.00157	0.00295	CcSEcCtD
Epoprostenol—Infection—Sorafenib—thyroid cancer	0.00156	0.00293	CcSEcCtD
Epoprostenol—Shock—Sorafenib—thyroid cancer	0.00154	0.0029	CcSEcCtD
Epoprostenol—Nervous system disorder—Sorafenib—thyroid cancer	0.00154	0.00289	CcSEcCtD
Epoprostenol—Dizziness—Vandetanib—thyroid cancer	0.00154	0.00289	CcSEcCtD
Epoprostenol—PTGIS—Disease—CHST14—thyroid cancer	0.00154	0.00343	CbGpPWpGaD
Epoprostenol—Thrombocytopenia—Sorafenib—thyroid cancer	0.00153	0.00289	CcSEcCtD
Epoprostenol—Skin disorder—Sorafenib—thyroid cancer	0.00152	0.00287	CcSEcCtD
Epoprostenol—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00152	0.00286	CcSEcCtD
Epoprostenol—Neck pain—Doxorubicin—thyroid cancer	0.00152	0.00286	CcSEcCtD
Epoprostenol—Pulmonary embolism—Doxorubicin—thyroid cancer	0.0015	0.00283	CcSEcCtD
Epoprostenol—Anorexia—Sorafenib—thyroid cancer	0.00149	0.00281	CcSEcCtD
Epoprostenol—Injection site reaction—Doxorubicin—thyroid cancer	0.00149	0.00281	CcSEcCtD
Epoprostenol—Cramps of lower extremities—Epirubicin—thyroid cancer	0.00149	0.00281	CcSEcCtD
Epoprostenol—Vomiting—Vandetanib—thyroid cancer	0.00148	0.00278	CcSEcCtD
Epoprostenol—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00148	0.00278	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—CALCB—thyroid cancer	0.00147	0.00327	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CALCB—thyroid cancer	0.00147	0.00327	CbGpPWpGaD
Epoprostenol—Rash—Vandetanib—thyroid cancer	0.00147	0.00276	CcSEcCtD
Epoprostenol—Dermatitis—Vandetanib—thyroid cancer	0.00146	0.00276	CcSEcCtD
Epoprostenol—Influenza like illness—Doxorubicin—thyroid cancer	0.00146	0.00275	CcSEcCtD
Epoprostenol—Headache—Vandetanib—thyroid cancer	0.00146	0.00274	CcSEcCtD
Epoprostenol—PTGIS—Disease—TRIM33—thyroid cancer	0.00146	0.00325	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CALCB—thyroid cancer	0.00145	0.00323	CbGpPWpGaD
Epoprostenol—Pulmonary oedema—Epirubicin—thyroid cancer	0.00145	0.00272	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00144	0.00322	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00143	0.00269	CcSEcCtD
Epoprostenol—Sepsis—Epirubicin—thyroid cancer	0.00141	0.00265	CcSEcCtD
Epoprostenol—Dyspnoea—Sorafenib—thyroid cancer	0.0014	0.00263	CcSEcCtD
Epoprostenol—Nausea—Vandetanib—thyroid cancer	0.00138	0.0026	CcSEcCtD
Epoprostenol—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00138	0.0026	CcSEcCtD
Epoprostenol—Dyspepsia—Sorafenib—thyroid cancer	0.00138	0.0026	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—NDUFA13—thyroid cancer	0.00137	0.00305	CbGpPWpGaD
Epoprostenol—Decreased appetite—Sorafenib—thyroid cancer	0.00136	0.00257	CcSEcCtD
Epoprostenol—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00136	0.00303	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00135	0.00255	CcSEcCtD
Epoprostenol—Fatigue—Sorafenib—thyroid cancer	0.00135	0.00255	CcSEcCtD
Epoprostenol—Constipation—Sorafenib—thyroid cancer	0.00134	0.00252	CcSEcCtD
Epoprostenol—Pain—Sorafenib—thyroid cancer	0.00134	0.00252	CcSEcCtD
Epoprostenol—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00134	0.00252	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00133	0.00298	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CALCB—thyroid cancer	0.00133	0.00297	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CALCB—thyroid cancer	0.00133	0.00297	CbGpPWpGaD
Epoprostenol—PTGIR—lymph node—thyroid cancer	0.00133	0.064	CbGeAlD
Epoprostenol—Hepatic failure—Epirubicin—thyroid cancer	0.00131	0.00247	CcSEcCtD
Epoprostenol—Eczema—Epirubicin—thyroid cancer	0.00131	0.00247	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—TSHR—thyroid cancer	0.00131	0.00291	CbGpPWpGaD
Epoprostenol—Sepsis—Doxorubicin—thyroid cancer	0.0013	0.00246	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CHST14—thyroid cancer	0.00129	0.00287	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00128	0.00241	CcSEcCtD
Epoprostenol—Urticaria—Sorafenib—thyroid cancer	0.00125	0.00235	CcSEcCtD
Epoprostenol—Body temperature increased—Sorafenib—thyroid cancer	0.00124	0.00233	CcSEcCtD
Epoprostenol—Abdominal pain—Sorafenib—thyroid cancer	0.00124	0.00233	CcSEcCtD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00123	0.00274	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00123	0.00274	CbGpPWpGaD
Epoprostenol—Hepatic failure—Doxorubicin—thyroid cancer	0.00121	0.00229	CcSEcCtD
Epoprostenol—Eczema—Doxorubicin—thyroid cancer	0.00121	0.00229	CcSEcCtD
Epoprostenol—Cardiac failure—Epirubicin—thyroid cancer	0.00121	0.00227	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—TSHR—thyroid cancer	0.0012	0.00268	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—TSHR—thyroid cancer	0.0012	0.00268	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.0012	0.00267	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Sorafenib—thyroid cancer	0.00115	0.00217	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—PRKAR1A—thyroid cancer	0.00115	0.00256	CbGpPWpGaD
Epoprostenol—Asthenia—Sorafenib—thyroid cancer	0.00112	0.00212	CcSEcCtD
Epoprostenol—Cardiac failure—Doxorubicin—thyroid cancer	0.00112	0.0021	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—PTCH1—thyroid cancer	0.00111	0.00248	CbGpPWpGaD
Epoprostenol—Pruritus—Sorafenib—thyroid cancer	0.00111	0.00209	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00108	0.00203	CcSEcCtD
Epoprostenol—Diarrhoea—Sorafenib—thyroid cancer	0.00107	0.00202	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—PRKAR1A—thyroid cancer	0.00106	0.00236	CbGpPWpGaD
Epoprostenol—Gastritis—Epirubicin—thyroid cancer	0.00104	0.00196	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—HPGD—thyroid cancer	0.00104	0.00231	CbGpPWpGaD
Epoprostenol—Dizziness—Sorafenib—thyroid cancer	0.00104	0.00195	CcSEcCtD
Epoprostenol—Abdominal distension—Epirubicin—thyroid cancer	0.00103	0.00193	CcSEcCtD
Epoprostenol—PTGIR—GPCR ligand binding—PTCH1—thyroid cancer	0.00102	0.00228	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—PTCH1—thyroid cancer	0.00102	0.00228	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—SST—thyroid cancer	0.00102	0.00227	CbGpPWpGaD
Epoprostenol—Vomiting—Sorafenib—thyroid cancer	0.000997	0.00188	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000996	0.00188	CcSEcCtD
Epoprostenol—Rash—Sorafenib—thyroid cancer	0.000988	0.00186	CcSEcCtD
Epoprostenol—Dermatitis—Sorafenib—thyroid cancer	0.000987	0.00186	CcSEcCtD
Epoprostenol—Headache—Sorafenib—thyroid cancer	0.000982	0.00185	CcSEcCtD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—AKT1—thyroid cancer	0.000982	0.00219	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CALCA—thyroid cancer	0.000978	0.00218	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TCF7L1—thyroid cancer	0.000971	0.00217	CbGpPWpGaD
Epoprostenol—Pancytopenia—Epirubicin—thyroid cancer	0.000967	0.00182	CcSEcCtD
Epoprostenol—Gastritis—Doxorubicin—thyroid cancer	0.000965	0.00182	CcSEcCtD
Epoprostenol—Abdominal distension—Doxorubicin—thyroid cancer	0.000949	0.00179	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—SST—thyroid cancer	0.000935	0.00209	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—SST—thyroid cancer	0.000935	0.00209	CbGpPWpGaD
Epoprostenol—Nausea—Sorafenib—thyroid cancer	0.000931	0.00175	CcSEcCtD
Epoprostenol—Weight decreased—Epirubicin—thyroid cancer	0.000922	0.00174	CcSEcCtD
Epoprostenol—Pneumonia—Epirubicin—thyroid cancer	0.000914	0.00172	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—thyroid cancer	0.000908	0.00171	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—thyroid cancer	0.000908	0.00171	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CALCA—thyroid cancer	0.0009	0.00201	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CALCA—thyroid cancer	0.0009	0.00201	CbGpPWpGaD
Epoprostenol—Pancytopenia—Doxorubicin—thyroid cancer	0.000895	0.00169	CcSEcCtD
Epoprostenol—Urinary tract infection—Epirubicin—thyroid cancer	0.000883	0.00166	CcSEcCtD
Epoprostenol—Sweating—Epirubicin—thyroid cancer	0.000871	0.00164	CcSEcCtD
Epoprostenol—Haematuria—Epirubicin—thyroid cancer	0.000866	0.00163	CcSEcCtD
Epoprostenol—Epistaxis—Epirubicin—thyroid cancer	0.000857	0.00161	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—CALCB—thyroid cancer	0.000855	0.00191	CbGpPWpGaD
Epoprostenol—Weight decreased—Doxorubicin—thyroid cancer	0.000853	0.00161	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—thyroid cancer	0.000852	0.0016	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—thyroid cancer	0.000845	0.00159	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000841	0.00188	CbGpPWpGaD
Epoprostenol—Infestation—Doxorubicin—thyroid cancer	0.00084	0.00158	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—thyroid cancer	0.00084	0.00158	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—thyroid cancer	0.00083	0.00156	CcSEcCtD
Epoprostenol—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000822	0.00183	CbGpPWpGaD
Epoprostenol—Haemoglobin—Epirubicin—thyroid cancer	0.00082	0.00154	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—thyroid cancer	0.000817	0.00154	CcSEcCtD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000817	0.00182	CbGpPWpGaD
Epoprostenol—Urinary tract infection—Doxorubicin—thyroid cancer	0.000817	0.00154	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—thyroid cancer	0.000815	0.00154	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—thyroid cancer	0.000811	0.00153	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—TRIM33—thyroid cancer	0.000811	0.00181	CbGpPWpGaD
Epoprostenol—Pharyngitis—Epirubicin—thyroid cancer	0.000809	0.00152	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—thyroid cancer	0.000806	0.00152	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—thyroid cancer	0.000803	0.00151	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—thyroid cancer	0.000801	0.00151	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—thyroid cancer	0.000801	0.00151	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—thyroid cancer	0.000793	0.00149	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—thyroid cancer	0.000789	0.00148	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—CALCB—thyroid cancer	0.000787	0.00176	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CALCB—thyroid cancer	0.000787	0.00176	CbGpPWpGaD
Epoprostenol—Bradycardia—Doxorubicin—thyroid cancer	0.000768	0.00145	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IFNA2—thyroid cancer	0.000761	0.0017	CbGpPWpGaD
Epoprostenol—Haemoglobin—Doxorubicin—thyroid cancer	0.000758	0.00143	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—thyroid cancer	0.000757	0.00143	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—thyroid cancer	0.000757	0.00143	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—thyroid cancer	0.000756	0.00142	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—thyroid cancer	0.000754	0.00142	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000751	0.00141	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—thyroid cancer	0.000749	0.00141	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—TRIM33—thyroid cancer	0.000746	0.00166	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TRIM33—thyroid cancer	0.000746	0.00166	CbGpPWpGaD
Epoprostenol—Oedema peripheral—Doxorubicin—thyroid cancer	0.000743	0.0014	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000741	0.0014	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—thyroid cancer	0.00074	0.00139	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—TSHR—thyroid cancer	0.000738	0.00165	CbGpPWpGaD
Epoprostenol—Mediastinal disorder—Epirubicin—thyroid cancer	0.000735	0.00138	CcSEcCtD
Epoprostenol—Chills—Epirubicin—thyroid cancer	0.000732	0.00138	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—thyroid cancer	0.000714	0.00135	CcSEcCtD
Epoprostenol—PTGIS—Disease—TPR—thyroid cancer	0.000711	0.00159	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IFNA2—thyroid cancer	0.0007	0.00156	CbGpPWpGaD
Epoprostenol—Flushing—Doxorubicin—thyroid cancer	0.0007	0.00132	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—thyroid cancer	0.0007	0.00132	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—thyroid cancer	0.000699	0.00132	CcSEcCtD
Epoprostenol—PTGIS—Disease—PRKAR1A—thyroid cancer	0.000699	0.00156	CbGpPWpGaD
Epoprostenol—Tension—Epirubicin—thyroid cancer	0.000697	0.00131	CcSEcCtD
Epoprostenol—Nervousness—Epirubicin—thyroid cancer	0.000689	0.0013	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—thyroid cancer	0.000687	0.00129	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—thyroid cancer	0.000685	0.00129	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—thyroid cancer	0.000682	0.00129	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00068	0.00128	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—TSHR—thyroid cancer	0.000679	0.00152	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—TSHR—thyroid cancer	0.000679	0.00152	CbGpPWpGaD
Epoprostenol—Chills—Doxorubicin—thyroid cancer	0.000677	0.00127	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—TSHR—thyroid cancer	0.00067	0.0015	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MEN1—thyroid cancer	0.000668	0.00149	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000666	0.00149	CbGpPWpGaD
Epoprostenol—Mental disorder—Doxorubicin—thyroid cancer	0.000661	0.00124	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000659	0.00147	CbGpPWpGaD
Epoprostenol—Anaemia—Epirubicin—thyroid cancer	0.000656	0.00124	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—thyroid cancer	0.000652	0.00123	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—thyroid cancer	0.000647	0.00122	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—thyroid cancer	0.000645	0.00121	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—thyroid cancer	0.000638	0.0012	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—thyroid cancer	0.000637	0.0012	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—thyroid cancer	0.000635	0.0012	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—thyroid cancer	0.000631	0.00119	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—thyroid cancer	0.000627	0.00118	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—thyroid cancer	0.000624	0.00117	CcSEcCtD
Epoprostenol—Cough—Epirubicin—thyroid cancer	0.000619	0.00117	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—TSHR—thyroid cancer	0.000617	0.00138	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—TSHR—thyroid cancer	0.000617	0.00138	CbGpPWpGaD
Epoprostenol—Anaemia—Doxorubicin—thyroid cancer	0.000607	0.00114	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000607	0.00135	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000607	0.00135	CbGpPWpGaD
Epoprostenol—Chest pain—Epirubicin—thyroid cancer	0.000604	0.00114	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—thyroid cancer	0.000604	0.00114	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—thyroid cancer	0.000604	0.00114	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—thyroid cancer	0.000604	0.00114	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—thyroid cancer	0.000602	0.00113	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.0006	0.00113	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—TPR—thyroid cancer	0.000595	0.00133	CbGpPWpGaD
Epoprostenol—Dry mouth—Epirubicin—thyroid cancer	0.000591	0.00111	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—thyroid cancer	0.000589	0.00111	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—PRKAR1A—thyroid cancer	0.000586	0.00131	CbGpPWpGaD
Epoprostenol—Confusional state—Epirubicin—thyroid cancer	0.000584	0.0011	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—thyroid cancer	0.00058	0.00109	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—thyroid cancer	0.000579	0.00109	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—thyroid cancer	0.000579	0.00109	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—thyroid cancer	0.000577	0.00109	CcSEcCtD
Epoprostenol—Infection—Epirubicin—thyroid cancer	0.000576	0.00108	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—SST—thyroid cancer	0.000574	0.00128	CbGpPWpGaD
Epoprostenol—Cough—Doxorubicin—thyroid cancer	0.000573	0.00108	CcSEcCtD
Epoprostenol—Shock—Epirubicin—thyroid cancer	0.00057	0.00107	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—PTCH1—thyroid cancer	0.00057	0.00127	CbGpPWpGaD
Epoprostenol—Nervous system disorder—Epirubicin—thyroid cancer	0.000568	0.00107	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—thyroid cancer	0.000567	0.00107	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—thyroid cancer	0.000565	0.00106	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—thyroid cancer	0.000563	0.00106	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—thyroid cancer	0.00056	0.00105	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—thyroid cancer	0.000559	0.00105	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—thyroid cancer	0.000559	0.00105	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—thyroid cancer	0.000559	0.00105	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—thyroid cancer	0.000557	0.00105	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000555	0.00105	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CALCA—thyroid cancer	0.000553	0.00123	CbGpPWpGaD
Epoprostenol—Anorexia—Epirubicin—thyroid cancer	0.000552	0.00104	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—thyroid cancer	0.000547	0.00103	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—thyroid cancer	0.000541	0.00102	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—TCF7L1—thyroid cancer	0.000541	0.00121	CbGpPWpGaD
Epoprostenol—Confusional state—Doxorubicin—thyroid cancer	0.00054	0.00102	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—thyroid cancer	0.000536	0.00101	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000536	0.00101	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—thyroid cancer	0.000533	0.001	CcSEcCtD
Epoprostenol—PTGIS—Disease—CALCA—thyroid cancer	0.000532	0.00119	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000531	0.00118	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—SST—thyroid cancer	0.000528	0.00118	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—SST—thyroid cancer	0.000528	0.00118	CbGpPWpGaD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000528	0.000994	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—thyroid cancer	0.000527	0.000993	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—thyroid cancer	0.000526	0.00099	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000525	0.000988	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—PTCH1—thyroid cancer	0.000524	0.00117	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PTCH1—thyroid cancer	0.000524	0.00117	CbGpPWpGaD
Epoprostenol—Insomnia—Epirubicin—thyroid cancer	0.000524	0.000987	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—thyroid cancer	0.000523	0.000985	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—SST—thyroid cancer	0.000521	0.00116	CbGpPWpGaD
Epoprostenol—Skin disorder—Doxorubicin—thyroid cancer	0.000521	0.00098	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—thyroid cancer	0.00052	0.00098	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000518	0.000976	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000518	0.00116	CbGpPWpGaD
Epoprostenol—Dyspnoea—Epirubicin—thyroid cancer	0.000516	0.000973	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—thyroid cancer	0.000515	0.00097	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—thyroid cancer	0.000511	0.000962	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—thyroid cancer	0.00051	0.00096	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—CALCA—thyroid cancer	0.000508	0.00113	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CALCA—thyroid cancer	0.000508	0.00113	CbGpPWpGaD
Epoprostenol—Decreased appetite—Epirubicin—thyroid cancer	0.000504	0.000948	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CALCA—thyroid cancer	0.000502	0.00112	CbGpPWpGaD
Epoprostenol—Hypotension—Doxorubicin—thyroid cancer	0.000501	0.000943	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0005	0.000942	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—thyroid cancer	0.000499	0.000941	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—TCF7L1—thyroid cancer	0.000498	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TCF7L1—thyroid cancer	0.000498	0.00111	CbGpPWpGaD
Epoprostenol—Pain—Epirubicin—thyroid cancer	0.000495	0.000933	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—thyroid cancer	0.000495	0.000933	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000488	0.00092	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—thyroid cancer	0.000485	0.000913	CcSEcCtD
Epoprostenol—PTGIS—Disease—CDK1—thyroid cancer	0.000482	0.00107	CbGpPWpGaD
Epoprostenol—Paraesthesia—Doxorubicin—thyroid cancer	0.000481	0.000906	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—SST—thyroid cancer	0.00048	0.00107	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—SST—thyroid cancer	0.00048	0.00107	CbGpPWpGaD
Epoprostenol—Dyspnoea—Doxorubicin—thyroid cancer	0.000478	0.0009	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—thyroid cancer	0.000477	0.000897	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000474	0.000892	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000472	0.00105	CbGpPWpGaD
Epoprostenol—Dyspepsia—Doxorubicin—thyroid cancer	0.000472	0.000889	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—thyroid cancer	0.000466	0.000877	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000463	0.000871	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—thyroid cancer	0.000462	0.00087	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—CALCA—thyroid cancer	0.000462	0.00103	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CALCA—thyroid cancer	0.000462	0.00103	CbGpPWpGaD
Epoprostenol—Urticaria—Epirubicin—thyroid cancer	0.00046	0.000867	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—thyroid cancer	0.000458	0.000863	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—thyroid cancer	0.000458	0.000863	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—thyroid cancer	0.000458	0.000862	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—thyroid cancer	0.000458	0.000862	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CDK1—thyroid cancer	0.000454	0.00101	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000446	0.000995	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—SLC5A5—thyroid cancer	0.000446	0.000994	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000438	0.000825	CcSEcCtD
Epoprostenol—Hypersensitivity—Epirubicin—thyroid cancer	0.000427	0.000804	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—thyroid cancer	0.000426	0.000802	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—thyroid cancer	0.000424	0.000798	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—thyroid cancer	0.000424	0.000798	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CDK1—thyroid cancer	0.000418	0.000933	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CDK1—thyroid cancer	0.000418	0.000933	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000418	0.000932	CbGpPWpGaD
Epoprostenol—Asthenia—Epirubicin—thyroid cancer	0.000416	0.000783	CcSEcCtD
Epoprostenol—Pruritus—Epirubicin—thyroid cancer	0.00041	0.000772	CcSEcCtD
Epoprostenol—Diarrhoea—Epirubicin—thyroid cancer	0.000396	0.000746	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—TSHR—thyroid cancer	0.000396	0.000883	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Doxorubicin—thyroid cancer	0.000395	0.000744	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—PRKAR1A—thyroid cancer	0.00039	0.000869	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRG1—thyroid cancer	0.000387	0.000863	CbGpPWpGaD
Epoprostenol—Asthenia—Doxorubicin—thyroid cancer	0.000385	0.000724	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—thyroid cancer	0.000383	0.000721	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—thyroid cancer	0.000379	0.000714	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000379	0.000846	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000376	0.000839	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—RXRA—thyroid cancer	0.000374	0.000835	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MEN1—thyroid cancer	0.000372	0.000831	CbGpPWpGaD
Epoprostenol—Vomiting—Epirubicin—thyroid cancer	0.000368	0.000694	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—thyroid cancer	0.000367	0.000691	CcSEcCtD
Epoprostenol—Rash—Epirubicin—thyroid cancer	0.000365	0.000688	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—thyroid cancer	0.000365	0.000687	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—TSHR—thyroid cancer	0.000364	0.000813	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TSHR—thyroid cancer	0.000364	0.000813	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000364	0.000813	CbGpPWpGaD
Epoprostenol—Headache—Epirubicin—thyroid cancer	0.000363	0.000683	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000358	0.0008	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000358	0.0008	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	0.000356	0.000794	CbGpPWpGaD
Epoprostenol—Dizziness—Doxorubicin—thyroid cancer	0.000354	0.000668	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000354	0.000789	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TERT—thyroid cancer	0.000347	0.000775	CbGpPWpGaD
Epoprostenol—Nausea—Epirubicin—thyroid cancer	0.000344	0.000648	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—MEN1—thyroid cancer	0.000343	0.000764	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MEN1—thyroid cancer	0.000343	0.000764	CbGpPWpGaD
Epoprostenol—Vomiting—Doxorubicin—thyroid cancer	0.000341	0.000642	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—thyroid cancer	0.000338	0.000636	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—thyroid cancer	0.000338	0.000636	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—PTCH1—thyroid cancer	0.000337	0.000751	CbGpPWpGaD
Epoprostenol—Headache—Doxorubicin—thyroid cancer	0.000336	0.000632	CcSEcCtD
Epoprostenol—PTGIS—Disease—HIF1A—thyroid cancer	0.000332	0.000741	CbGpPWpGaD
Epoprostenol—Nausea—Doxorubicin—thyroid cancer	0.000318	0.0006	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—PTCH1—thyroid cancer	0.00031	0.000691	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTCH1—thyroid cancer	0.00031	0.000691	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SST—thyroid cancer	0.000308	0.000687	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CALCA—thyroid cancer	0.000296	0.000661	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NRAS—thyroid cancer	0.000284	0.000633	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SST—thyroid cancer	0.000283	0.000632	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SST—thyroid cancer	0.000283	0.000632	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—BRAF—thyroid cancer	0.000275	0.000613	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CALCA—thyroid cancer	0.000273	0.000609	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CALCA—thyroid cancer	0.000273	0.000609	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDK1—thyroid cancer	0.000268	0.000599	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NRAS—thyroid cancer	0.000261	0.000583	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MINPP1—thyroid cancer	0.00026	0.00058	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDK1—thyroid cancer	0.000247	0.000551	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDK1—thyroid cancer	0.000247	0.000551	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KRAS—thyroid cancer	0.000244	0.000545	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPARG—thyroid cancer	0.000236	0.000528	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KRAS—thyroid cancer	0.000225	0.000502	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—thyroid cancer	0.000222	0.000495	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NDUFA13—thyroid cancer	0.000221	0.000493	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—thyroid cancer	0.000217	0.000484	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRG1—thyroid cancer	0.000215	0.00048	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CHST14—thyroid cancer	0.000208	0.000464	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—thyroid cancer	0.000208	0.000463	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—thyroid cancer	0.0002	0.000446	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRG1—thyroid cancer	0.000198	0.000442	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRG1—thyroid cancer	0.000198	0.000442	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—thyroid cancer	0.000194	0.000432	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TERT—thyroid cancer	0.000193	0.000431	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—thyroid cancer	0.000191	0.000426	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—thyroid cancer	0.000186	0.000415	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIF1A—thyroid cancer	0.000185	0.000413	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—thyroid cancer	0.000183	0.000409	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TERT—thyroid cancer	0.000178	0.000397	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TERT—thyroid cancer	0.000178	0.000397	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRAS—thyroid cancer	0.000173	0.000386	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIF1A—thyroid cancer	0.00017	0.00038	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIF1A—thyroid cancer	0.00017	0.00038	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—thyroid cancer	0.000169	0.000377	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPGD—thyroid cancer	0.000168	0.000374	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—NRAS—thyroid cancer	0.000163	0.000363	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—thyroid cancer	0.000162	0.000362	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BRAF—thyroid cancer	0.000153	0.000342	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NRAS—thyroid cancer	0.00015	0.000334	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—NRAS—thyroid cancer	0.00015	0.000334	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—thyroid cancer	0.000149	0.000332	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BRAF—thyroid cancer	0.000141	0.000314	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BRAF—thyroid cancer	0.000141	0.000314	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—thyroid cancer	0.00014	0.000313	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000136	0.000303	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—thyroid cancer	0.000129	0.000288	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—thyroid cancer	0.000129	0.000288	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—thyroid cancer	0.000126	0.000282	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—thyroid cancer	0.000119	0.000266	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—thyroid cancer	0.000116	0.000259	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—thyroid cancer	0.000112	0.000249	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—thyroid cancer	0.000112	0.000249	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—thyroid cancer	0.00011	0.000245	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—thyroid cancer	0.00011	0.000245	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—thyroid cancer	0.000108	0.000241	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—thyroid cancer	0.000107	0.000238	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—thyroid cancer	0.000107	0.000238	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—thyroid cancer	0.000105	0.000235	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—thyroid cancer	0.000103	0.000229	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—thyroid cancer	0.000103	0.000229	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—thyroid cancer	9.93e-05	0.000221	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—thyroid cancer	9.93e-05	0.000221	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—thyroid cancer	9.68e-05	0.000216	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—thyroid cancer	9.68e-05	0.000216	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRAS—thyroid cancer	9.62e-05	0.000215	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TPR—thyroid cancer	9.62e-05	0.000215	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	9.46e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—thyroid cancer	9.35e-05	0.000209	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRAS—thyroid cancer	8.86e-05	0.000198	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRAS—thyroid cancer	8.86e-05	0.000198	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	8.58e-05	0.000191	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—thyroid cancer	8.28e-05	0.000185	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—thyroid cancer	7.62e-05	0.00017	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—thyroid cancer	7.62e-05	0.00017	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—thyroid cancer	7.36e-05	0.000164	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A5—thyroid cancer	7.2e-05	0.000161	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—thyroid cancer	7.04e-05	0.000157	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—thyroid cancer	6.78e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—thyroid cancer	6.78e-05	0.000151	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	6.75e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—thyroid cancer	6.48e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—thyroid cancer	6.48e-05	0.000145	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—thyroid cancer	6.22e-05	0.000139	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—RXRA—thyroid cancer	6.05e-05	0.000135	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.89e-05	0.000131	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—thyroid cancer	5.72e-05	0.000128	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—thyroid cancer	5.72e-05	0.000128	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—thyroid cancer	3.82e-05	8.52e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—thyroid cancer	3.01e-05	6.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—thyroid cancer	2.62e-05	5.85e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—thyroid cancer	1.51e-05	3.37e-05	CbGpPWpGaD
